Association between amyloid-β42 levels and neuropsychiatric symptoms in Alzheimer's disease trials.

ABSTRACT: Research on how Alzheimer's disease drugs impact neuropsychiatric symptoms is limited. Given the link between changes in cerebrospinal fluid (CSF) amyloid-β42 (Aβ42) levels and cognitive and clinical outcomes after anti-Aβ treatments, we hypothesized a similar association exists with neuropsychiatric symptoms. We conducted a meta-analysis of anti-Aβ drugs clinical trials to evaluate whether the changes in cerebrospinal Aβ42 levels are associated with neuropsychiatric symptoms, as measured by the Neuropsychiatric Inventory and if any such effect is mediated by changes in cognitive performance, as measured by the Mini-Mental State Examination. Data from 10 trials involving 10 746 Alzheimer's disease patients were included. Decreases in Aβ42 levels were associated with worsening Neuropsychiat

SUBMITTER: Abanto JT 

PROVIDER: S-EPMC11879397 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature